Cohort study for patients with aggressive lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational cohort study enrolls patients diagnosed with aggressive forms of lymphoma, including Hodgkin and non-Hodgkin lymphomas. Participants will receive treatment according to standard clinical practices at the institution, and their disease status, response to therapy, and survival will be monitored throughout the study. Blood samples will be collected to analyze serum and cell-free DNA, providing insights into the disease's progression and treatment efficacy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas
2. 20 years
3. Patients requiring systemic chemotherapy with curative intent
4. Written informed consent

Exclusion Criteria:

1. Myeloid malignancy
2. Multiple myeloma
3. Patients do not require systemic chemotherapy with curative intent

Where it's running

• Samsung Medical Center
  Seoul, South Korea Recruiting

Study contacts

• Principal investigator: Seok Jin Kim, MD, PhD — Samsung Medical Center
• Study coordinator: Seok Jin Kim, MD, PhD
• Email: kstwoh@skku.edu
• Phone: +82234101766

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Breaking up long sitting periods to improve heart health and reduce chemo side effects in adults with lymphoma on R-CHOP or POLA-R-CHP

  This trial will test whether a 12-week program that interrupts long periods of sitting helps newly diagnosed adults with lymphoma receiving R-CHOP or POLA-R-CHP chemotherapy improve heart health and reduce chemotherapy side effects.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06923397

• Depleting specific immune cells in stem cell transplants for blood cancers

  This study is testing if removing certain immune cells during stem cell transplants can help children and young adults with blood cancers have better outcomes and fewer complications.

  Recruiting Phase 2 University of Florida · Gainesville, Florida · NCT05800210

• JMBI-001 in MYC-Positive Advanced Cancers

  This study tests JMBI-001 to see if it is safe and tolerable for adults with MYC-positive advanced cancers.

  Recruiting Phase 1/2 Chengdu Anticancer Bioscience, Ltd. · Beijing, Beijing Municipality · NCT07864701

• UB-VV400 with rapamycin in relapsed/refractory B-cell lymphomas

  A phase 1/2 trial tests UB-VV400 plus rapamycin in adults with relapsed or refractory B-cell lymphomas to see if it is safe and shows anti-tumor activity.

  Recruiting at 2 sites Phase 1/2 Umoja Biopharma · Irvine, California and 1 other locations · NCT07735533

• Toxin exposure and immune factors in B-cell non-Hodgkin lymphoma

  This study tests how toxin exposure, genetics, and immune issues relate to B-cell non-Hodgkin lymphoma in active-duty service members and other Military Health System beneficiaries.

  Recruiting Henry M. Jackson Foundation for the Advancement of Military Medicine · Bethesda, Maryland and 2 other locations · NCT07652580

• GSK5926371 in adults with relapsed or refractory B-cell non-Hodgkin lymphoma

  We’re testing whether GSK5926371 is safe and can show activity in adults whose B-cell non-Hodgkin lymphoma has come back or not responded to prior treatment.

  Recruiting at 22 sites Phase 1/2 GlaxoSmithKline · Iowa City, Iowa and 21 other locations · NCT07607925

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.